GlycoMimetics Inc.

0.25
0.01 (4.73%)
At close: Apr 24, 2025, 3:59 PM
0.26
2.02%
After-hours: Apr 24, 2025, 07:38 PM EDT
4.73%
Bid 0.23
Market Cap 16.26M
Revenue (ttm) n/a
Net Income (ttm) -37.88M
EPS (ttm) -0.59
PE Ratio (ttm) -0.43
Forward PE -7.99
Analyst n/a
Ask 0.28
Volume 1,047,586
Avg. Volume (20D) 1,439,203
Open 0.25
Previous Close 0.24
Day's Range 0.24 - 0.26
52-Week Range 0.14 - 1.93
Beta 1.74

About GLYC

GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as in phase 3 trial to treat relapsed/refractory AML. In addition, the company is developing G...

Industry Biotechnology
Sector Healthcare
IPO Date Jan 10, 2014
Employees 4
Stock Exchange NASDAQ
Ticker Symbol GLYC
Full Company Profile
5 months ago
+191.32%
GlycoMimetics shares are trading higher after the ... Unlock content with Pro Subscription
10 months ago
+25.28%
GlycoMimetics shares are trading higher after the company disclosed that Chief Medical Officer Edwin Rock bought 305,000 shares at an average price of $0.26 per share.